173 related articles for article (PubMed ID: 11495589)
1. Human thioredoxin reductase is efficiently inhibited by (2,2':6',2' '-terpyridine)platinum(II) complexes. Possible implications for a novel antitumor strategy.
Becker K; Herold-Mende C; Park JJ; Lowe G; Schirmer RH
J Med Chem; 2001 Aug; 44(17):2784-92. PubMed ID: 11495589
[TBL] [Abstract][Full Text] [Related]
2. Terpyridine-platinum(II) complexes are effective inhibitors of mammalian topoisomerases and human thioredoxin reductase 1.
Lo YC; Ko TP; Su WC; Su TL; Wang AH
J Inorg Biochem; 2009 Jul; 103(7):1082-92. PubMed ID: 19525010
[TBL] [Abstract][Full Text] [Related]
3. (2,2':6',2"-Terpyridine)platinum(II) complexes are irreversible inhibitors of Trypanosoma cruzi trypanothione reductase but not of human glutathione reductase.
Bonse S; Richards JM; Ross SA; Lowe G; Krauth-Siegel RL
J Med Chem; 2000 Dec; 43(25):4812-21. PubMed ID: 11123991
[TBL] [Abstract][Full Text] [Related]
4. Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents.
Engman L; Cotgreave I; Angulo M; Taylor CW; Paine-Murrieta GD; Powis G
Anticancer Res; 1997; 17(6D):4599-605. PubMed ID: 9494575
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds.
Witte AB; Anestål K; Jerremalm E; Ehrsson H; Arnér ES
Free Radic Biol Med; 2005 Sep; 39(5):696-703. PubMed ID: 16085187
[TBL] [Abstract][Full Text] [Related]
6. Transfer of 4'-chloro-2,2':6',2"-terpyridine platinum(II) between human serum albumin, glutathione and other thiolate ligands. A possible selective natural transport mechanism for the delivery of platinum(II) drugs to tumour cells.
Ross SA; Carr CA; Brïet JW; Lowe G
Anticancer Drug Des; 2000 Dec; 15(6):431-9. PubMed ID: 11716436
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex.
Arnér ES; Nakamura H; Sasada T; Yodoi J; Holmgren A; Spyrou G
Free Radic Biol Med; 2001 Nov; 31(10):1170-8. PubMed ID: 11705695
[TBL] [Abstract][Full Text] [Related]
8. Potent Inhibition of Thioredoxin Reductase by the Rh Derivatives of Anticancer M(arene/Cp*)(NHC)Cl
Truong D; Sullivan MP; Tong KKH; Steel TR; Prause A; Lovett JH; Andersen JW; Jamieson SMF; Harris HH; Ott I; Weekley CM; Hummitzsch K; Söhnel T; Hanif M; Metzler-Nolte N; Goldstone DC; Hartinger CG
Inorg Chem; 2020 Mar; 59(5):3281-3289. PubMed ID: 32073260
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors.
Qiu X; Liu Z; Shao WY; Liu X; Jing DP; Yu YJ; An LK; Huang SL; Bu XZ; Huang ZS; Gu LQ
Bioorg Med Chem; 2008 Sep; 16(17):8035-41. PubMed ID: 18678491
[TBL] [Abstract][Full Text] [Related]
10. Restraining Cancer Cells by Dual Metabolic Inhibition with a Mitochondrion-Targeted Platinum(II) Complex.
Wang K; Zhu C; He Y; Zhang Z; Zhou W; Muhammad N; Guo Y; Wang X; Guo Z
Angew Chem Int Ed Engl; 2019 Mar; 58(14):4638-4643. PubMed ID: 30693616
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of 5-nitro-2-furancarbohydrazides and their cis-diamminedichloroplatinum complexes as bitopic and irreversible human thioredoxin reductase inhibitors.
Millet R; Urig S; Jacob J; Amtmann E; Moulinoux JP; Gromer S; Becker K; Davioud-Charvet E
J Med Chem; 2005 Nov; 48(22):7024-39. PubMed ID: 16250662
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the cell growth inhibitory effects of a novel DNA-intercalating bipyridyl-thiourea-Pt(II) complex in cisplatin-sensitive and -resistant human ovarian cancer cells.
Marverti G; Ligabue A; Montanari M; Guerrieri D; Cusumano M; Di Pietro ML; Troiano L; Di Vono E; Iotti S; Farruggia G; Wolf F; Monti MG; Frassineti C
Invest New Drugs; 2011 Feb; 29(1):73-86. PubMed ID: 19834646
[TBL] [Abstract][Full Text] [Related]
13. Applying the designed multiple ligands approach to inhibit dihydrofolate reductase and thioredoxin reductase for anti-proliferative activity.
Ng HL; Chen S; Chew EH; Chui WK
Eur J Med Chem; 2016 Jun; 115():63-74. PubMed ID: 26994844
[TBL] [Abstract][Full Text] [Related]
14. Antiglioma activity of 2,2':6',2"-terpyridineplatinum(II) complexes in a rat model--effects on cellular redox metabolism.
Ahmadi R; Urig S; Hartmann M; Helmke BM; Koncarevic S; Allenberger B; Kienhoefer C; Neher M; Steiner HH; Unterberg A; Herold-Mende C; Becker K
Free Radic Biol Med; 2006 Mar; 40(5):763-78. PubMed ID: 16520229
[TBL] [Abstract][Full Text] [Related]
15. Preparation of 4-([2,2':6',2″-terpyridin]-4'-yl)-N,N-diethylaniline Ni(II) and Pt(II) complexes and exploration of their in vitro cytotoxic activities.
Zou HH; Wang L; Long ZX; Qin QP; Song ZK; Xie T; Zhang SH; Liu YC; Lin B; Chen ZF
Eur J Med Chem; 2016 Jan; 108():1-12. PubMed ID: 26619388
[TBL] [Abstract][Full Text] [Related]
16. Current Progresses in Metal-based Anticancer Complexes as Mammalian TrxR Inhibitors.
Cheng Y; Qi Y
Anticancer Agents Med Chem; 2017; 17(8):1046-1069. PubMed ID: 28270080
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Thioredoxin Reductase by Triosmium Carbonyl Clusters.
Koh WX; Coppo L; Holmgren A; Kong JW; Leong WK
Chem Res Toxicol; 2020 Sep; 33(9):2441-2445. PubMed ID: 32786549
[TBL] [Abstract][Full Text] [Related]
18. Metal complexes with 2-acetylpyridine-N(4)-orthochlorophenylthiosemicarbazone: cytotoxicity and effect on the enzymatic activity of thioredoxin reductase and glutathione reductase.
Parrilha GL; Ferraz KS; Lessa JA; de Oliveira KN; Rodrigues BL; Ramos JP; Souza-Fagundes EM; Ott I; Beraldo H
Eur J Med Chem; 2014 Sep; 84():537-44. PubMed ID: 25058344
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of 2,2'-bipyridyl-6-carbothioamide: a ribonucleotide reductase inhibitor.
Nocentini G; Barzi A
Gen Pharmacol; 1997 Nov; 29(5):701-6. PubMed ID: 9347313
[TBL] [Abstract][Full Text] [Related]
20. A Novel Platinum-based Compound with Preferential Cytotoxic Activity against a Panel of Cancer Cell Lines.
Shahsavar F; Bozorgmehr M; Mirzadegan E; Abedi A; Lighvan ZM; Mohammadi F; Safari N; Amani V; Zarnani AH
Anticancer Agents Med Chem; 2016; 16(3):393-403. PubMed ID: 26899296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
